James Quigley Stock Analyst Profile - Goldman Sachs Research Coverage - Stocknear

James Quigley

Stock Analyst at Goldman Sachs

(4.02)
# 2020
Out of 5,506 analysts
30
Total ratings
Success rate
Average return

8 Stocks

Name Action PT Current % Upside Ratings Updated
NVS Novartis
Downgrades: Sell
119 118
132.42 -10.89% 2 Sep 12, 2025
KYMR Kymera Therapeutics
Upgrades: Overweight
49 79
57.9 36.44% 6 Jun 3, 2025
SNY Sanofi
Initiates Coverage On: Neutral
65
50.9 27.7% 1 Mar 21, 2025
MOR MorphoSys
Downgrades: Equal-Weight
n/a
n/a n/a 6 Jan 19, 2024
GRFS Grifols
Maintains: Neutral
10 11
9.95 5.53% 1 Dec 5, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
42 40
37.62 6.33% 10 Aug 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
12 16
4.01 299% 3 Jun 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
25
n/a n/a 1 Nov 20, 2017